Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside

Zhou，Qifan1; Yang，Sidi2,3; Cao，Liu2; Yang，Yang4; Xu，Tiefeng2; Chen，Qishu1; Lu，Hongzhou4; Li，Yingjun1; Guo，Deyin2,3; Zhang，Xumu1; Zhou，Qifan5; Yang，Sidi6,7; Cao，Liu6; Yang，Yang8; Xu，Tiefeng6; Chen，Qishu5; Lu，Hongzhou8; Li，Yingjun5; Guo，Deyin6,7; Zhang，Xumu5

2022-12-01

10.1038/s41392-023-01310-0

Signal Transduction and Targeted Therapy   Impact Factor & Quartile

2095-9907

2059-3635

SCI

English

First ; Corresponding

National Outstanding Youth Science Fund Project of National Natural Science Foundation of China[32041002] ; Science, Technology and Innovation Commission of Shenzhen Municipality[JSGG20200225150431472] ; Science, Technology and Innovation Commission of Shenzhen Municipality[JSGG20210901145403012] ; Science, Technology and Innovation Commission of Shenzhen Municipality[KQTD20180411143323605]

Biochemistry & Molecular Biology ; Cell Biology

Biochemistry & Molecular Biology ; Cell Biology

WOS:000913489900001

SPRINGERNATURE

2-s2.0-85146297327

Scopus

1.Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis,Department of Chemistry,College of Science,Academy for Advanced Interdisciplinary Studies and Medi-X Pingshan,Southern University of Science and Technology,Shenzhen,Guangdong,518000,China
2.Centre for Infection and Immunity Studies (CIIS),School of Medicine,Shenzhen,Shenzhen Campus of Sun Yat-sen University, Guangdong,518107,China
3.Guangzhou Laboratory,Bio-Island,Guangzhou,China
4.Shenzhen Key Laboratory of Pathogen and Immunity,National Clinical Research Center for infectious disease,State Key Discipline of Infectious Disease,Shenzhen Third People′s Hospital,Second Hospital Affiliated to Southern University of Science and Technology,Shenzhen,China
5.Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis,Department of Chemistry,College of Science,Academy for Advanced Interdisciplinary Studies and Medi-X Pingshan,Southern University of Science and Technology,Shenzhen,Guangdong,518000,China
6.Centre for Infection and Immunity Studies (CIIS),School of Medicine,Shenzhen,Shenzhen Campus of Sun Yat-sen University, Guangdong,518107,China
7.Guangzhou Laboratory,Bio-Island,Guangzhou,China
8.Shenzhen Key Laboratory of Pathogen and Immunity,National Clinical Research Center for infectious disease,State Key Discipline of Infectious Disease,Shenzhen Third People′s Hospital,Second Hospital Affiliated to Southern University of Science and Technology,Shenzhen,China

Zhou，Qifan,Yang，Sidi,Cao，Liu,等. Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside[J]. Signal Transduction and Targeted Therapy,2022,8(1).

Zhou，Qifan.,Yang，Sidi.,Cao，Liu.,Yang，Yang.,Xu，Tiefeng.,...&Zhang，Xumu.(2022).Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside.Signal Transduction and Targeted Therapy,8(1).

Zhou，Qifan,et al."Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside".Signal Transduction and Targeted Therapy 8.1(2022).